Spilios Manolakopoulos

Prof. Spilios Manolakopoulos


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
ETEmmanuel A. Tsochatzis
Emmanuel A. Tsochatzis
SMSpilios Manolakopoulos
Spilios Manolakopoulos
George PapatheodoridisGeorge Papatheodoridis
George Papatheodoridis
AAAthanasios J. Archimandritis
Athanasios J. Archimandritis
Insulin resistance (IR) and metabolic syndrome have recently been implicated in the pathogenesis and progression of chronic liver diseases, especially chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD). In this review, we provide current information on their deleterious effect on the liver, with particular interest in those two entities. In NAFLD, IR causes both the accumulation of fat in hepatocytes and the progression to non-alcoholic steatohepatitis (NASH). Moreover, the presence of metabolic syndrome seems to be associated with severe fibrosis in NASH patients. In CHC, IR develops early in the course of the disease and precedes steatosis. It is also independently associated with histological severity and negatively affects treatment response, irrespective of genotype. Consequently, therapies targeting IR and metabolic syndrome could indirectly ameliorate the prognosis of both NAFLD and CHC. As specific therapies do not exist, patients with metabolic syndrome and CHC and NAFLD should be counseled to lose weight and ameliorate their glycemic control and lipid profile.

16 September 2010 in Liver International
Verified
Journal Article
Open access
PDF file
SMSpilios Manolakopoulos
Spilios Manolakopoulos
MDMelanie Deutsch
Melanie Deutsch
OAOlga Anagnostou
Olga Anagnostou
SKStelios Karatapanis
Stelios Karatapanis
ETElli Tiniakou
Elli Tiniakou
AAAthanasios J. Archimandritis
Athanasios J. Archimandritis
International guidelines and routine clinical practice express concerns about antiviral treatment in intravenous drug users (IDUs). We analysed the effect of IDU and/or substitution therapy on chronic hepatitis C (CHC) treatment adherence and response. Intravenous drug users with CHC were divided into three groups: (A) patients on a substitution programme; (B) active users; and (C) past IDUs. Patients were treated according to the standard of care and followed by a specialist team. A total of 175 patients (mean age 39.4±8.8) were included. One hundred and forty-four (65%) were adherent to therapy (completing treatment and 6 months of follow-up). Twenty-two patients (36%) discontinued because of side effects, 28 (46%) discontinued on their own and 11 (18%) completed treatment but did not present at follow-up. Of 142 patients with available treatment outcome, 99 (69.7%) achieved a sustained virological response (SVR), with no differences among the study groups. Patients with genotypes 2-3 and those who completed the treatment schedule had 2.78-fold (95% CI: 1.3-5.8) and 6.4-fold (95% CI: 2.6-15.6) higher probability of achieving SVR. Active use of illicit drugs and/or drug substitution do not affect the treatment outcome in patients with CHC as long as they are closely followed and remain adherent to the treatment.

10 August 2024 in Diseases
Verified
Journal Article
Open access
PDF file
Christos LionisChristos Lionis
Christos Lionis
SPSophia Papadakis
Sophia Papadakis
MAMarilena Anastasaki
Marilena Anastasaki
EAEftihis Aligizakis
Eftihis Aligizakis
FAFoteini Anastasiou
Foteini Anastasiou
ITIoanna Tsiligianni
Ioanna Tsiligianni
Background: Despite its high prevalence and impact on health, metabolic dysfunction-associated steatotic liver disease (MASLD) is inadequately addressed in European primary care (PC), with a large proportion of cases going undiagnosed or diagnosed too late. A multi-country European research consortium led a project to design and evaluate a patient-centered, integrated model for MASLD screening, diagnosis, and linkage to specialty care for European PC settings. Based on the lessons from this project, the latest research evidence, and existing guidelines for the management of MASLD, we sought to develop a set of practice recommendations for screening, referral, and management of MASLD in PC. Methods: The Rand/UCLA modified Delphi panel method, with two rounds, was used to reach consensus on practice recommendations. The international panel consisted of experts from six countries, representing family medicine, gastroenterology, hepatology, cardiology, and public health. Initially, fifteen statements were drafted based on a synthesis of evidence from the literature and earlier findings from our consortium. Prior to the consensus meeting, the statements were rated by the experts in the first round. Then, in a hybrid meeting, the experts discussed findings from round one, adjusted the statements, and reassessed the updated recommendations in a second round. Results: In round one, there was already a high level of consensus on 10 out of 15 statements. After round 2, there were fourteen statements with a high degree of agreement (>90%). One statement was not endorsed. The approved recommendations addressed the following practice areas: risk screening and diagnosis, management of MASLD–lifestyle interventions, pharmacological treatment of MASLD/MASH, pharmacological treatment for co-morbidity, integrated care, surgical management, and other referrals to specialists. Conclusions: The final set of 14 recommendations focuses on increasing comprehensive care for MASLD in PC. The recommendations provide practical evidence-based guidance tailored to PC practitioners. We expect that these recommendations will contribute to the ongoing discussion on systematic approaches to tackling MASLD and supporting European PC providers by integrating the latest evidence into practice.

1 November 2021 in Liver International
Verified
Journal Article
Open access
PDF file
AGAnestis Goulas
Anestis Goulas
GKGeorgia Kafiri
Georgia Kafiri
Hariklia KranidiotiHariklia Kranidioti
Hariklia Kranidioti
SMSpilios Manolakopoulos
Spilios Manolakopoulos
Recently in the Liver International, three patients1,2 with AIH during COVID-19 were reported. Τhere is also increasing evidence that vaccination for SARS-CoV-2 may induce autoimmunity3,4. Here, we present a case of histologically confirmed AIH after mRNA vaccination against SARS-CoV-2. A 52-years-old Caucasian woman with no medication history or alcohol abuse and normal liver blood tests during previous periodical checkup, received her 1st dose of the Moderna vaccine on 11th of May 2021.

Verified
Journal Article
Open access
PDF file
ETEleni-Myrto Trifylli
Eleni-Myrto Trifylli
Anastasios G. KriebardisAnastasios G. Kriebardis
Anastasios G. Kriebardis
Evangelos KoustasEvangelos Koustas
Evangelos Koustas
NPNikolaos Papadopoulos
Nikolaos Papadopoulos
SVSofia Vasileiadi
Sofia Vasileiadi
MDMelanie Deutsch
Melanie Deutsch
Cholangiocarcinomas (CCAs) constitute a heterogeneous group of highly malignant epithelial tumors arising from the biliary tree. This cluster of malignant tumors includes three distinct entities, the intrahepatic, perihilar, and distal CCAs, which are characterized by different epidemiological and molecular backgrounds, as well as prognosis and therapeutic approaches. The higher incidence of CCA over the last decades, the late diagnostic time that contributes to a high mortality and poor prognosis, as well as its chemoresistance, intensified the efforts of the scientific community for the development of novel diagnostic tools and therapeutic approaches. Extracellular vesicles (EVs) comprise highly heterogenic, multi-sized, membrane-enclosed nanostructures that are secreted by a large variety of cells via different routes of biogenesis. Their role in intercellular communication via their cargo that potentially contributes to disease development and progression, as well as their prospect as diagnostic biomarkers and therapeutic tools, has become the focus of interest of several current studies for several diseases, including CCA. The aim of this review is to give a rundown of the current knowledge regarding the emerging role of EVs in cholangiocarcinogenesis and their future perspectives as diagnostic and therapeutic tools.

6 October 2009 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ETE. Tsochatzis
E. Tsochatzis
SMSpilios Manolakopoulos
Spilios Manolakopoulos
George PapatheodoridisGeorge Papatheodoridis
George Papatheodoridis
EHEmilia Hadziyannis
Emilia Hadziyannis
Christos TriantosChristos Triantos
Christos Triantos
AAA. J. Archimandritis
A. J. Archimandritis